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Background/introduction
By preventing more than 98% of currently used pharama-
ceutical agents from entering the brain, the blood-brain
barrier critically reduces the ability of therapeutics to
treat a variety of central nervous system (CNS) disorders
including glioblastoma and neurodegenerative diseases.
Focused ultrasound (FUS) mediated microbubble oscilla-
tion and subsequent blood brain barrier (BBB) permeabi-
lization has been explored as a powerful non-invasive
strategy for the delivery of circulating therapeutic agents
into the CNS. FUS in conjunction with microbubbles has
been shown to facilitate non-damaging, reversible and
localized disruption of the BBB, leading to substantial
increases in nanoparticle (NP) concentrations in ultra-
sound-treated tissue. Once beyond the BBB, the extracel-
lular matrix acts as a steric and adhesive barrier and
limits NP distribution. Coating sub-100 nm nanoparticles
with a dense brush layer of polyethylene glycol (PEG) to
limit the interactions with the ECM leads to a significant
improvement of their diffusivity in brain tissue. The
current study investigates the ability of FUS to deliver
densely PEGylated brain penetrating cationic polymer-
based gene vectors across the BBB to mediate robust and
long-term transgene expression.
Methods
Anesthetized 200g Sprague-Dawley rats were secured in
a stereotaxic frame and their heads were depilated. A
1.5-inch single element 1MHz focused ultrasound trans-
ducer was ultrasonically coupled. The tail vein was cannu-
lated, and a coinjection of microbubbles (105/g) and 50
nm PEGylated polyethylenimine (PEG-PEI) nanoparticles
(50 ug, 100 ug, 200 ug or 350 ug doses) immediately pre-
ceded ultrasound treatment. We delivered luciferase and
mCherry transgenes under control of a beta-actin promo-
ter. All sonications were performed with a 0.5% duty cycle,
a total time of two minutes, and a peak negative pressure
of 0.6 MPa. Luciferase expression was assessed through
bioluminescent imaging following a 150 mg/kg injection
of luciferin in an In Vivo Imaging System. Following
euthanasia, animals were perfused with saline, and brains
were dehydrated and cryosectioned. Mounted sections
were stained with mCherry, Draq5 or H&E.
Results and conclusions
Delivery of luciferase-bearing PEG-PEI NP resulted in
robust bioluminescence through day 28, the last day
tested. Bioluminescence was dose-dependent (Figure 1).
Under H&E, no signs of histological defect were found at
the lowest two doses administered, while the 200 ug dose
had only a single site of minor damage. In order to assess
transfection efficiency rat brains treated with FUS and
200 ug of mCherry-expressing PEG-PEI seven days prior
were sectioned and stained with a marker for cell nuclei.
41% of cells in the FUS-treated region were found to
express the mCherry reporter gene compared to only 6%
on the contralateral non-treated region. FUS mediated
BBB disruption presents a novel platform for drug and
gene delivery technologies to the brain. Our results indi-
cate that robust gene expression can be achieved by sys-
temically delivering densely PEGylated cationic polymer
gene vectors and that transgene expression can be main-
tained for at least 28 days. Currently, we are analyzing
the therapeutic efficacy of FUS-mediated gene therapy in
a rat model of neurodegenerative disease.
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Figure 1 FUS mediated delivery of luciferase-bearing PEG-PEI NP
mediates targeted, dose-dependent bioluminescence in a rat.
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